Department of Respiratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Acta Oncol. 2012 Feb;51(2):151-6. doi: 10.3109/0284186X.2011.631579. Epub 2011 Nov 16.
Severe adverse events (AEs) have been reported in cancer patients treated with bevacizumab. Currently, safety of bevacizumab in patients with non-small cell lung cancer (NSCLC) is not clear. We conducted a meta-analysis to evaluate the risk profile of bevacizumab in NSCLC patients.
Relevant trials were identified by searching databases and conference proceedings. Data on treatment-related deaths and grade 3 or 4 AEs were extracted and pooled to calculate relative risks (RRs) with 95% confidence interval (CI) for bevacizumab compared with chemotherapy alone.
A total of 2210 patients were included in the analysis. Compared with chemotherapy alone, high-dosage (15 mg/kg) bevacizumab was associated with an increased risk of treatment-related deaths (RR = 2.04, 95% CI = 1.18-3.52), but not for low-dosage (7.5 mg/kg) group (RR = 1.20, 95% CI = 0.60-2.41). In addition, treatment with bevacizumab was associated with several grade 3 or 4 AEs in patients with NSCLC, especially in high-dosage bevacizumab group.
The use of the bevacizumab increases the risk of treatment-related deaths and several grade 3 or 4 AEs in patient with NSCLC. The risk may be dose-dependent. Close monitoring and adequate management are recommended to decrease severe AEs.
接受贝伐珠单抗治疗的癌症患者报告了严重的不良事件 (AE)。目前，贝伐珠单抗在非小细胞肺癌 (NSCLC) 患者中的安全性尚不清楚。我们进行了一项荟萃分析，以评估贝伐珠单抗在 NSCLC 患者中的风险概况。
通过搜索数据库和会议记录确定相关试验。提取并汇总与治疗相关的死亡和 3 或 4 级 AE 相关的数据，以计算贝伐珠单抗与单独化疗相比的相对风险 (RR)，置信区间 (CI) 为 95%。
共有 2210 名患者纳入分析。与单独化疗相比，高剂量 (15 mg/kg) 贝伐珠单抗与治疗相关的死亡风险增加相关 (RR = 2.04，95% CI = 1.18-3.52)，但低剂量 (7.5 mg/kg) 组无此关联 (RR = 1.20，95% CI = 0.60-2.41)。此外，贝伐珠单抗治疗与 NSCLC 患者的几种 3 或 4 级 AE 相关，尤其是高剂量贝伐珠单抗组。
贝伐珠单抗的使用增加了 NSCLC 患者与治疗相关的死亡风险和几种 3 或 4 级 AE。风险可能与剂量有关。建议密切监测和充分管理，以减少严重 AE。
